PUBLISHER: The Business Research Company | PRODUCT CODE: 1390930
PUBLISHER: The Business Research Company | PRODUCT CODE: 1390930
“Acute Agitation And Aggression Treatment Market Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute agitation and aggression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acute agitation and aggression treatment market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute agitation and aggression treatment market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
Treatment for acute agitation and aggression addresses the sudden onset of restlessness, irritability, and hostility in patients, aiming to manage and alleviate these symptoms. Such behaviors can be manifestations of underlying conditions like psychiatric disorders, neurological issues, or substance use or withdrawal effects.
The primary methods for managing acute agitation and aggression encompass behavioral, environmental, and pharmacological approaches. The behavioral approach involves the scientific study of observable behavior and its environmental triggers, emphasizing psychological perspectives. Pharmacologic approaches often employ diverse drugs, such as anti-psychotics, benzodiazepines, and others, administered through various routes like oral or intramuscular. These treatments target conditions such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation, alcohol withdrawal, and more. They are utilized across various settings, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare environments.
The acute agitation and aggression treatment market research report is one of a series of new reports from The Business Research Company that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute agitation & aggression treatment market size has grown strongly in recent years. It will grow from $5.4 in 2023 to $5.72 in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth observed during the historic period can be attributed to several factors, including advancements in pharmacology, increased emphasis on clinical research, regulatory approvals for new treatments, a higher prevalence of cases related to acute agitation and aggression, and an enhanced awareness concerning mental health.
The acute agitation & aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.23 in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be linked to several key factors such as the expanding aging population, increasing development of healthcare infrastructure, a rise in investments within the pharmaceutical industry, the escalation of home-based care services, and the overall growth in disposable income. Major trends expected during this forecast period encompass non-pharmacological interventions, the advent of precision medicine, the integration of AI and predictive analytics, the emphasis on community-based support, and increased collaboration within the industry.
The anticipated expansion of the acute agitation and aggression treatment market is closely tied to several significant factors. Firstly, the increasing incidence of dementia is expected to be a driving force. Dementia, a condition marked by cognitive impairments and an inability to perform daily tasks, often leads to symptoms like agitation and restlessness. Effective treatment is crucial in managing these symptoms, improving the patient's quality of life, and addressing the root causes of agitation. For instance, according to data from the Australian Institute of Health and Welfare in February 2023, Australia is expected to see a substantial rise in dementia cases, reaching 849,300 by 2058, highlighting the need for treatments in this area.
The burden of mental illness is on the rise, further fueling the growth of the acute agitation and aggression treatment market. Mental illnesses impact various aspects of an individual's well-being, necessitating treatment for disruptive and potentially harmful behaviors. This treatment ensures both the patient's safety and the well-being of those around them. As per data from the NHS Business Services Authority in July 2021, there was a notable increase in the prescription of antidepressant medications in response to mental health challenges, emphasizing the growing demand for treatments in the mental health domain.
Major companies within the acute agitation and aggression treatment market are actively engaged in innovative product development and approvals, exemplified by IGALMI (dexmedetomidine). IGALMI, a sublingual film, has received FDA approval and offers a new treatment avenue for individuals dealing with agitation associated with schizophrenia or bipolar disorders. Developed by BioXcel Therapeutics Inc. in April 2022, this fast-acting and short-duration medication represents an advancement in addressing severe or life-threatening conditions. These developments contribute to the evolving landscape of treatments within the market.
Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
In April 2023, SK Capital Partners LP, a private investment firm based in the United States, completed the acquisition of Apotex Inc., a renowned Canada-based generic pharmaceutical company. The acquisition, for an undisclosed sum, represents a strategic move enabling SK Capital to broaden its presence within the generic pharmaceutical sector. Apotex's specialization in producing medications for treating acute agitation and aggression aligns with SK Capital's extended investment pursuits in the healthcare industry.
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
North America was the largest region in the acute agitation and aggression treatment market in 2023 . Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute agitation and aggression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute agitation and aggression treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.